1 | INTRODUCTION

Synovial sarcoma (SS) is the fourth most common sarcoma of the soft tissue, following liposarcoma, pleomorphic undifferentiated sarcoma, and rhabdomyosarcoma. With more prevalence in men than women. Most of the SS cases are located in extremities, predominantly lower extremities1–3, especially near large joints around the knee and thigh.4 SS has an annual incidence of 2.5 per 100,000.5 Intracranial SS is very uncommon and has been reported as a metastasis lesion from SS in other parts of the body.4,6–12 In this study, we report a case with no extracranial pathology, with recurrent primary intracranial SS, which has been very rarely reported in the literature.

2 | CASE PRESENTATION

The case study is devoted to investigating headache and left hemiplegia in a 28-year-old man 10 days before coming to the emergency room. Neurological examination revealed left-sided hemiplegia, without gait instability and ataxia. Brain computed tomography (CT) scan revealed an intra axial mass lesion with a central necrotic component and surrounding vasogenic edema in the right frontal white matter causing a midline shift to the left side (Figure 1). The patient underwent magnetic resonance imaging (MRI) with gadolinium contrast for more evaluation, and the findings were as mentioned below: an intra axial well-circumscribed heterogeneous mass with central necrosis and irregular peripheral enhancement and significant surrounding vasogenic edema in the right frontal white matter. Restriction of the peripheral solid component of mass was also seen (Figure 2).

The patient was taken to the operation room and underwent total excision of the mass. Many hours later the left hemiplegia gradually improved. The histopathological assessment of the mass revealed neoplastic tissue composed of biphasic pattern: large irregular sheets of monotonous cells some with central necrosis set in the fibroblastic stroma. Tumoral cells are plump and have a very high N/C ratio. Frequent mitotic figures are present (Figure 3).
IHC staining shows positive reactivity for TLE1, FLI1, and INI1 and negative reactivity for Synaptophysin, Olig2, SMA, CK and CD99. GFAP staining is nonspecific (Figure 4). The above findings are consistent with SS. The abdominopelvic CT scan was normal. Also, the PET scan did not show any other metastasis.

The patient was discharged 1 week after surgery without any neurological problems.

He underwent radiotherapy 1 month after his discharge.

Four months later, the patient came back to the neurology emergency room with left hemiplegia, he underwent CT scan findings that revealed a recurrence of the previous tumor (Figure 5), so he was taken to the operating room again and underwent total excision of the mass. The histopathological assessment showed SS recurrence. PET scan was done again and there was no evidence of primary SS anywhere else or any other metastasis. The patient was discharged 1 week later without any neurological signs or symptoms.

3 | DISCUSSION

SS is a form of soft tissue sarcoma that occurs mostly in young and middle-aged adults and has more tendency to occur in extremities, however, it can occurs in children and old individuals and involve other parts of the body. It is believed that 5–10 percent of soft tissue sarcomas are SS. The tumor is closely related to a tendon sheath, tendon, joint capsule, and bursal structures. It may also arise primarily in other parts of the body, such as the heart, kidney, and lungs. Synovial cell sarcomas arise from type B synoviocytes. There is an alternative sarcoma subtype, which originates from type A synoviocytes, called histiocytic sarcoma. There are four subtypes of SS, as mentioned below: monophasic, monophasic epithelial, biphasic, and poorly differentiated (round cell tumors). Classical SS has a biphasic morphology and its pathological findings are sheets of spindle cells and sharply segregated epithelial cells forming gland-like areas. The second form of SS is monophasic containing only a sarcomatous component. Most of the SSs are of these two forms mentioned earlier (4) IHC staining can be positive for epithelial markers (keratin and EMA) and CD99, S-100 protein, and BCL2. TLE1 is the most sensitive and specific marker for SS. Because the tumor resembled synovial tissue under the light microscope, it was named “Synovial Sarcoma” by Sabrazes in 1934. However, the cellular origin of this tumor is possibly from neural crest-derived malignant peripheral nerve cells. Chromosomal translocation of t(X;18)(p11.2;q11.2) can be investigated in over 95% of SS. The treatment of choice for primary tumors is excisional surgery, while metastatic SS cannot be treated with excisional surgery but chemotherapy and radiotherapy may help them. In addition, the current understanding of cancer cells has highlighted the importance of mitochondria in cancer biogenesis. This issue has been found specifically in SS. Besides, considering the 75% expression of PD-L1 on SS cells, one might assume that this modality might be applied in the future for primary intracranial SSs. Current literature has noted that the immunotherapy results can be improved by improving mitochondria biogenesis. In some patients, SS is diagnosed when it reaches out to other organs such as lungs, bone, and lymph nodes. Intracranial SS is very rare and in most cases is reported as a metastasis from SS. SS presenting as an intracranial has been reported very rarely, as mentioned below:

1. Kleinschmidt-DeMasters et al reported the case of a 19-year-old woman with primary synovial sarcoma of the third ventricle.
2. Bettio et al reported a 36-year-old man with a large intracranial tumor involving the cranial base, with the invasion of the sellar region and sphenoidal sinus.
3. Mohit Patel et al reported a primary intracranial synovial sarcoma as a right parietal heterogeneous, hyperdense mass with a large medial hematoma in a 21-year-old man.
4. Yang-Yang Wang et al reported a 35-year-old man with left intracerebral lesions with hemorrhage and left
FIGURE 2  Magnetic resonance imaging (MRI) without gadolinium contrast. A: T2 Flair Axial sequence. B: T2 Axial sequence. The above images show an intra axial well-circumscribed heterogeneous mass with central necrosis and surrounding vasogenic edema in right frontal white matter. Magnetic resonance imaging (MRI) with gadolinium contrast C: T1 Axial sequence without gadolinium contrast D: T1 with gadolinium contrast E: DWI sequence. The above images show an Intra axial well-circumscribed heterogenous mass with central necrosis and irregular peripheral enhancement and significant surrounding vasogenic edema in right frontal white matter. restriction of the peripheral solid component of mass was also seen

FIGURE 3 The histopathological assessment of the mass shows neoplastic tissue composed of biphasic pattern, large irregular sheets of monotonous cells, some with central necrosis set in fibroblastic stroma. Tumoral cells are plump and have very high N/C ratio. Frequent mitotic figures are present
middle cerebral artery arteriovenous malformation, respectively.\cite{30}

The clinical manifestations of primary intracranial SS are nonspecific, such as headache, nausea, vomiting, and hemiplegia. Radiologic features of primary SS are also nonspecific and the final diagnosis is made by pathological and immunohistochemistry features.\cite{30}

Our patient was a 28-year-old man with a headache and left hemiplegia. Neurological examination revealed

FIGURE 4  IHC staining shows positive reactivity for TLE1, FLI1, and INI1 and negative reactivity for Synaptophysin, Olig 2, SMA, CK and CD 99. The above findings are consistent with SS.
left-sided hemiplegia, without gait instability and ataxia. Brain computed tomography (CT) scan revealed an intraxial mass lesion with a central necrotic component and surrounding vasogenic edema in right frontal white matter causing midline shift to the left side. The patient underwent MRI with gadolinium contrast for more evaluation, and the findings were as mentioned below: An intraxial well-circumscribed heterogeneous mass with central necrosis and irregular peripheral enhancement and significant surrounding vasogenic edema in right frontal white matter. Restriction of the peripheral solid component of mass was also seen. The patient was taken to the operation room and underwent total excision of the mass. Many hours later, the left hemiplegia was gradually improved. The histopathological assessment of the mass revealed neoplastic tissue composed of biphasic patterns: large irregular sheets of monotonous cells some with central necrosis set in the fibroblastic stroma. Tumoral cells are plump and have a very high N/C ratio. Frequent mitotic figures are present.

IHC staining show positive reactivity for TLE1, FEI1, and INI1 and negative reactivity for Synaptophysin, Olig 2, SMA, CK CD 99. GFAP staining is nonspecific. The aforementioned findings are consistent with SS. The PET scan did not show any other metastatic disease. The abdominopelvic CT scan was also normal.

4 | CONCLUSION

SS is one of the most common sarcomas of soft tissue, and it mostly occurs in the lower extremities. It can cause metastatic disease, especially in the lungs, bones, and lymph nodes. Metastasis in the brain is very rare. Primary intracranial SS has also been reported extremely rare. In this article, we present a 28-year-old man with primary intracranial SS. It can be misdiagnosed with other intracranial masses. So, it is important to confirm the diagnosis with pathology and resect the tumor and start radiotherapy treatment if needed.

AUTHOR CONTRIBUTION

MAK and IM chose the case, reported the CT scan and MRI and supervised manuscript preparation. ZHT reviewed the published literature and wrote the case report manuscript. AS reviewed the published literature, interviewed the patient, and collected the patient past medical history. MAK, IM, and AS edited the written manuscript. All the authors read and approved the final manuscript.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

The authors declare that there are no competing interests.

DATA AVAILABILITY STATEMENT

Data sharing not applicable - no new data generated Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ETHICAL APPROVAL

All the ethics standards and consent were obtained for this manuscript.

CONSENT

Written informed consent for publication was obtained from the patient.

ORCID

Zhale Tabrizi

https://orcid.org/0000-0002-4961-1713

REFERENCES

1. Ladenstein R, Gadner H, Treuner J, et al. Synovial sarcoma of childhood and adolescence. report of the german CWS-81 study. Cancer. 1993;71(11):3647-3655.
2. van der Heide HJ, Veth RP, Pruszczynski M, Wobbes T, van Hoese QG, Lemmens JA. Synovial sarcoma: oncological and functional results. Eur J Surg Oncol. 1998;24(2):114-119.
3. Kallen ME, Hornick JL. The 2020 WHO classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol. 2021;45(1):e1-e23.
4. Nuwal P, Dixit R, Shah NS, Samaria A. Primary monophasic synovial sarcoma lung with brain metastasis diagnosed on trans-thoracic FNAC: report of a case with literature review. Lung India. 2012;29(4):384-387.
5. Scully SP, Temple H, Harrelson JM. Synovial sarcoma of the foot and ankle. Clin Orthop Relat Res. 1999;364:220-226.
6. Yoshida S, Morii K, Watanabe M, Saito T. Brain metastasis in patients with sarcoma: an analysis of histological subtypes, clinical characteristics, and outcomes. Surg Neurol. 2000;54(2):160-164.
7. Flannery K, Kano H, Niranjan A, et al. Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases. International journal of radiation oncology* biology*. Phys Ther. 2010;76(2):513-519.
8. Grossman R, Ram Z. Recursive partitioning analysis (RPA) classification predicts survival in patients with brain metastases from sarcoma. World Neurosurg. 2014;82(6):1291-1294.
9. Kaufman J, Tsukada Y. Synovial sarcoma with hemorrhage. Arch Orthop Trauma Surg. 2003;123(7):376-378.
10. Snyder LE, Yoon S, Goyal P, et al. Synovial sarcoma of the extremities: prognostic factors for 20 nonmetastatic cases. Cancer. 1976;38(1):96-99.
11. Baptista AM, Camargo OP, Croci AT, et al. Synovial sarcoma of the soft tissues: prognostic significance of the extremities, clinical characteristics, and outcomes. Surg Neurol. 2000;54(2):160-164.
12. Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N. Intracranial metastasis from synovial sarcoma. Orthopedics (Online). 2008;31(4):405.
13. Grossman R, Ram Z. Recursive partitioning analysis (RPA) classification predicts survival in patients with brain metastases from sarcoma. World Neurosurg. 2014;82(6):1291-1294.
14. Kaufman J, Tsukada Y. Synovial sarcoma with hemorrhage. Arch Orthop Trauma Surg. 2003;123(7):376-378.
15. Siegel HJ, Dunham WH, Lopez-Ben R, Siegal GP. Intracranial synovial sarcoma—unusual presentation with cerebral hemorrhage. Arch Orthop Trauma Surg. 2003;123(7):376-378.
16. Liptak JM, Forrest LJ. Soft tissue sarcomas. Small Animal Clinical Oncology. 2007;4:425-454.
17. Shahrokh S, Rakhasha A, Shahin M, et al. Successful treatment of central nervous system histiocytic sarcoma with craniectomy and adjuvant radiotherapy. Cureus. 2022;14(5):e24690.
18. Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009;26(1):1-10.
19. Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009;26(1):1-10.
20. Nosrati A, Shafiiee S, Aazam E. Case report: a 27 years old woman with brain metastases of synovial sarcoma. Inter J Med Invest. 2016;5(2):69-72.
21. Murray PM. Soft tissue sarcoma of the upper extremity. Hand Clin. 2004;20(3):325-333.
22. Taghizadeh-Hesary F, Akbari H, Bahadori M. Anti-Mitochondrial Therapy: A Potential Therapeutic Approach in Oncology. 2022. Preprints.
23. Su BC, Li CC, Horng JL, Chen YJ. Calcium-dependent calpain activation-mediated mitochondrial dysfunction and oxidative stress are required for cytotoxicity of Epinecicin-1 in human synovial sarcoma SW982 cells. Int J Mol Sci. 2020;21(6):2109.
24. Clemente O, Ottaiano A, Lorenzo G, et al. Is immunotherapy in the future of therapeutic management of sarcomas? J Transl Med. 2021;19(1):1-24.
25. Akbari H, Taghizadeh-Hesary F, Bahadori M. Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: an evidence-based hypothesis. Mitochondrion. 2022;62:151-158.
26. Rong R, Doxtader EE, Tull J, de la Roza G, Zhang S. Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis. Int J Clin Exp Pathol. 2010;3(2):217.
27. Patel M, Li L, Nguyen HS, Doan N, Sinson G, Mueller W. Primary intracranial synovial sarcoma. Case Rep Neurol Med. 2016;2016:1-4.
28. Kleinschmidt-Demasters BK, Mierau GW, Sze C-I, et al. Unusual dural and skull-based mesenchymal neoplasms: a report of four cases. Hum Pathol. 1998;29(3):240-245.
29. Bettio D, Rizzi N, Colombo P, Bianchi P, Gaetani P. Unusual cytogenetic findings in a synovial sarcoma arising in the paranasal sinuses. Cancer Genet Cytogenet. 2004;155(1):79-81.
30. Wang Y-Y, Li M-L, Zhang Z-Y, et al. Primary intracranial synovial sarcoma with hemorrhage: a case report. World J Clin Cases. 2021;9(29):8871-8878.

How to cite this article: Manizhe AK, Mohseni I, Sahranavard A, Tabrizi Z. Recurrent primary intracranial synovial sarcoma, a case report and review of the literature. Clin Case Rep. 2022;10:e06273. doi: 10.1002/ccr3.6273